Since weight loss drugs have come online, the weight loss industry has ballooned from about $76 billion a year to almost $90 billion in 2023.

Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). GLP-1 receptor agonist drugs commercialized by those firms have started a revolution in weight loss.

Weight-loss drugs like Ozempic and Zepbound are taking the pharmaceutical industry by storm. Investors want in.

About 1 in 8 U.S. adults (12%) have tried a weight-loss drug like Wegovy, Ozempic, Zepbound or Mounjaro, a new KFF Health Tracking Poll says.

One in eight US adults has tried medications from the fast-growing class of new diabetes and obesity drugs that includes Ozempic and Zepbound,

With the rise in popularity of weight loss drugs such as Ozempic, discussions about weight loss are once again ramping up. But while some people are open about using medication to slim down — or slimming down as a result of using medication to treat a condition such as type 2 diabetes — others consider commenting on or speculating about someone

To others, one of its main side effects—sudden, fast weight loss—means its appeal lies solely in the significant amount of pounds they can shed while on the medication. But what happens inside the body if you lose weight rapidly?

Genetics or hormonal changes can pose challenges for losing weight, as you may know firsthand. Like many others struggling to shed excess pounds, you might be wondering if the injectable medication Ozempic is right for you — and if so,